دورية أكاديمية
أعرض في EDS

Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia).

التفاصيل البيبلوغرافية
العنوان: Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia).
المؤلفون: Lin M; Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China., Chen B; Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China.
المصدر: Drug design, development and therapy [Drug Des Devel Ther] 2018 Apr 30; Vol. 12, pp. 1009-1017. Date of Electronic Publication: 2018 Apr 30 (Print Publication: 2018).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Dove Press Limited Country of Publication: New Zealand NLM ID: 101475745 Publication Model: eCollection Cited Medium: Internet ISSN: 1177-8881 (Electronic) Linking ISSN: 11778881 NLM ISO Abbreviation: Drug Des Devel Ther Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Auckland, N.Z.] : Dove Press Limited
مواضيع طبية MeSH: Antibodies, Monoclonal/*therapeutic use , Antineoplastic Agents/*therapeutic use , Leukemia, Myeloid, Acute/*drug therapy , Small Molecule Libraries/*therapeutic use, Humans
مستخلص: Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy, characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. The new drugs used for treating AML are facing a big challenge, and the candidates include cytotoxic drugs, targeted small-molecule inhibitors, and monoclonal antibodies. In recent years, active research has focused on several new agents for including them in the large antileukemic drug family. This review aims to introduce some of these new drugs and highlights new advances made in the old drugs, mainly in the last 5 years.
Competing Interests: Disclosure The authors report no conflicts of interest in this work.
References: Blood. 2015 Feb 26;125(9):1367-76. (PMID: 25550361)
Expert Rev Anticancer Ther. 2015;15(11):1261-6. (PMID: 26523431)
Leukemia. 2018 May;32(5):1168-1179. (PMID: 29472720)
Nature. 2012 Apr 15;485(7397):260-3. (PMID: 22504184)
Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):163-8.e1-2. (PMID: 26752456)
Lancet Oncol. 2015 Sep;16(9):1099-1110. (PMID: 26296954)
Curr Opin Pharmacol. 2012 Aug;12(4):398-402. (PMID: 22503290)
Lancet Oncol. 2009 Mar;10(3):223-32. (PMID: 19230772)
Haematologica. 2016 Mar;101(3):269-78. (PMID: 26928248)
Zhonghua Xue Ye Xue Za Zhi. 2016 Feb;37(2):100-4. (PMID: 27014977)
J Clin Oncol. 2011 Mar 10;29(8):979-85. (PMID: 21282541)
Indian J Hematol Blood Transfus. 2014 Dec;30(4):231-5. (PMID: 25435719)
J Clin Oncol. 2012 Jun 20;30(18):2204-10. (PMID: 22585696)
J Clin Oncol. 2013 Mar 1;31(7):923-9. (PMID: 23129738)
PLoS One. 2010 Apr 15;5(4):e10186. (PMID: 20419121)
Zhonghua Nei Ke Za Zhi. 2016 Apr 1;55(4):293-7. (PMID: 27030618)
J Clin Oncol. 2012 Jul 10;30(20):2441-8. (PMID: 22508825)
Blood. 2005 Jul 1;106(1):265-73. (PMID: 15769897)
Dalton Trans. 2015 Feb 7;44(5):2348-58. (PMID: 25534904)
Blood Cancer J. 2012 May;2(5):e69. (PMID: 22829971)
Blood. 2000 Dec 1;96(12):3907-14. (PMID: 11090077)
Am J Hematol. 2014 Oct;89(10):964-8. (PMID: 24990142)
Ther Adv Hematol. 2012 Feb;3(1):17-27. (PMID: 23556109)
Lancet Oncol. 2015 Sep;16(9):1025-1036. (PMID: 26234174)
PLoS One. 2010 Sep 29;5(9):. (PMID: 20927380)
Blood. 2012 Dec 6;120(24):4840-5. (PMID: 23071272)
Clin Cancer Res. 2008 Mar 1;14(5):1446-54. (PMID: 18316568)
Blood. 2013 Aug 22;122(8):1455-63. (PMID: 23770776)
Blood. 2001 Apr 15;97(8):2434-9. (PMID: 11290608)
J Clin Oncol. 2010 Feb 1;28(4):562-9. (PMID: 20026804)
Cancer. 2012 Jan 15;118(2):428-33. (PMID: 21717443)
Clin Cancer Res. 2016 Aug 15;22(16):4014-22. (PMID: 26920889)
J Clin Oncol. 2010 Feb 1;28(4):556-61. (PMID: 20026803)
Biochemistry. 2003 Jul 15;42(27):8232-9. (PMID: 12846572)
Cancer Res. 2006 Jun 15;66(12):6361-9. (PMID: 16778214)
Br J Haematol. 2014 Feb;164(4):481-95. (PMID: 24321020)
Leuk Res. 2010 Jul;34(7):899-905. (PMID: 20381863)
N Engl J Med. 2003 Nov 20;349(21):2042-54. (PMID: 14627790)
Expert Rev Anticancer Ther. 2016;16(2):137-46. (PMID: 26646091)
Blood. 2004 Mar 1;103(5):1635-40. (PMID: 14604977)
Acta Haematol. 2014;131(4):202-7. (PMID: 24296475)
Blood. 2014 Apr 3;123(14):2209-19. (PMID: 24532805)
J Natl Compr Canc Netw. 2015 May;13(5):508-14. (PMID: 25964636)
Semin Oncol. 2008 Aug;35(4):346-55. (PMID: 18692685)
Adv Biomed Res. 2012;1:54. (PMID: 23326785)
Leukemia. 2017 Feb;31(2):272-281. (PMID: 27721426)
Clin Cancer Res. 2013 Feb 1;19(3):721-30. (PMID: 23251007)
Br J Cancer. 2010 Oct 26;103(9):1391-9. (PMID: 20924380)
J Clin Oncol. 2010 Feb 1;28(4):549-55. (PMID: 20026805)
J Clin Oncol. 2012 Jul 20;30(21):2670-7. (PMID: 22689805)
Lancet Oncol. 2012 Nov;13(11):1096-104. (PMID: 23075701)
Leuk Lymphoma. 2016 Sep;57(9):2100-8. (PMID: 26784138)
Mol Pharmacol. 2001 Apr;59(4):725-31. (PMID: 11259616)
Blood. 2016 Feb 18;127(7):882-92. (PMID: 26286850)
Pediatr Blood Cancer. 2008 Jan;50(1):37-45. (PMID: 17420992)
Drug Metab Dispos. 2009 Mar;37(3):594-601. (PMID: 19074528)
Blood. 2014 May 22;123(21):3239-46. (PMID: 24687088)
J Clin Oncol. 2013 Sep 20;31(27):3360-8. (PMID: 23940227)
Zhonghua Xue Ye Xue Za Zhi. 2014 Jun;35(6):481-5. (PMID: 24985167)
Blood. 2012 Aug 30;120(9):1765-73. (PMID: 22677130)
Biotechnol Genet Eng Rev. 2017 Oct;33(2):190-226. (PMID: 29431047)
CA Cancer J Clin. 2017 Jan;67(1):7-30. (PMID: 28055103)
J Clin Oncol. 2014 Jan 20;32(3):219-28. (PMID: 24297940)
Blood. 2013 May 16;121(20):4166-74. (PMID: 23564911)
Haematologica. 2003 Jan;88(1):19-24. (PMID: 12551822)
Haematologica. 2011 Mar;96(3):393-9. (PMID: 21134979)
Pediatr Blood Cancer. 2014 Oct;61(10):1754-60. (PMID: 24976003)
فهرسة مساهمة: Keywords: 2017 NCCN guideline; acute myeloid leukemia; new drug therapies; refractory/relapsed AML
المشرفين على المادة: 0 (Antibodies, Monoclonal)
0 (Antineoplastic Agents)
0 (Small Molecule Libraries)
تواريخ الأحداث: Date Created: 20180512 Date Completed: 20180926 Latest Revision: 20240324
رمز التحديث: 20240324
مُعرف محوري في PubMed: PMC5933364
DOI: 10.2147/DDDT.S161199
PMID: 29750014
قاعدة البيانات: MEDLINE
الوصف
تدمد:1177-8881
DOI:10.2147/DDDT.S161199